Global Papillomavirus Hpv Testing Market

Papillomavirus Hpv Testing Comprehensive Study by Type (HPV Testing, Pap Test), Application (Cervical Cancer Screening, Vaginal Cancer Screening, Molecular Diagnostics, Research Use), End User (Laboratories, Hospitals, Diagnostic Centers, Clinics, Research Institutes), Product (DNA-based Test, RNA-based Test) Players and Region - Global Market Outlook to 2027

Papillomavirus Hpv Testing Market by XX Submarkets | Forecast Years 2023-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Papillomavirus Hpv Testing Market Scope
Diagnostics technology is advancing rapidly. The drivers driving market growth are the rising number of screening programmes and the rising prevalence of chronic diseases, such as vaginal and cervical cancer, worldwide. A laboratory procedure where cells are examined for DNA or RNA from certain HPV strains known to cause cervical cancer. These high-risk HPV variants can also result in malignancies of the anus, vagina, vulva, penis, and oropharynx, among other cancers. An HPV test, also known as primary HPV testing, may be used alone to screen for cervical cancer or in conjunction with a Pap test (called cotesting). The results of some abnormal Pap tests may also warrant an HPV test. Also known as a test for human papillomavirus.

AttributesDetails
Study Period2017-2027
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (United States), Greiner Bio-One International GmbH (Austria), Enzo Biochem Inc. (United States), Thermo Fisher Scientific Inc. (United States), Takara Bio Inc. (Japan), Agilent Technologies, Inc. (United States), Norgen Biotek Corp. (Canada), DiagCor Bioscience Inc Ltd (China), Hybribio Limited (China) and Zytovision GmbH (Germany)
CAGR%


The market for the Papillomavirus Hpv Testing is highly competitive and dominated by few key player. The market has a vendor landscape that is extremely competitive. A number of businesses are also taking part in significant mergers and acquisitions as part of crucial plans to increase their market share globally. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Papillomavirus Hpv Testing market throughout the predicted period.

Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (United States), Greiner Bio-One International GmbH (Austria), Enzo Biochem Inc. (United States), Thermo Fisher Scientific Inc. (United States), Takara Bio Inc. (Japan), Agilent Technologies, Inc. (United States), Norgen Biotek Corp. (Canada), DiagCor Bioscience Inc Ltd (China), Hybribio Limited (China) and Zytovision GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Becton, Dickinson and Company (United States), Qiagen N.V. (Netherland), Arbor Vita Corporation (United States), Medical & Biological Laboratories Co., Ltd (Japan) and Fujirebio Diagnostics, Inc. (Japan).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Papillomavirus Hpv Testing market by Type , by Application (Cervical Cancer Screening, Vaginal Cancer Screening, Molecular Diagnostics and Research Use) and Region with country level break-up.

On the basis of geography, the market of Papillomavirus Hpv Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies

On March 2021, a renowned provider of medical technology, BD (Becton, Dickinson and Company), has announced that the first self-collection claim for HPV screening to comply with the IVD Directive 98/79/EC has received CE marking. The new claim enables labs and facilities to use the BD OnclarityTM HPV Assay on either the BD ViperTM LT or the BD CORTM System to process self-collected samples using a BD diluent tube. The BD CORTM System, introduced last year, is in use all throughout Europe, while the BD ViperTM LT is in use globally


Influencing Trend:
The primary factor fuelling the market's expansion is the increase in awareness campaigns by different organisations

Market Growth Drivers:
The market is expanding due to an increase in cervical cancer screening programmes and Cervical cancer cases on the rise with an ageing population propelling the factor forward

Challenges:
Uncertain reimbursement policies hinder economic progress

Restraints:
Human papillomavirus vaccination is the factor hampering the market growth and Lack of skilled workforce restrict the market growth

Opportunities:
Technological advancement such as Artificial intelligence creates lucrative growth opportunities for the market and Government programmes and funding will produce attractive market expansion prospects

Key Target Audience
New Entrants and Investors, Laboratories, Hospitals, Diagnostic Centers, Clinics, Research Institutes, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • HPV Testing
  • Pap Test
By Application
  • Cervical Cancer Screening
  • Vaginal Cancer Screening
  • Molecular Diagnostics
  • Research Use
By End User
  • Laboratories
  • Hospitals
  • Diagnostic Centers
  • Clinics
  • Research Institutes

By Product
  • DNA-based Test
  • RNA-based Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The market is expanding due to an increase in cervical cancer screening programmes
      • 3.2.2. Cervical cancer cases on the rise with an ageing population propelling the factor forward
    • 3.3. Market Challenges
      • 3.3.1. Uncertain reimbursement policies hinder economic progress
    • 3.4. Market Trends
      • 3.4.1. The primary factor fuelling the market's expansion is the increase in awareness campaigns by different organisations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Papillomavirus Hpv Testing, by Type, Application, End User , Product and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Papillomavirus Hpv Testing (Value)
      • 5.2.1. Global Papillomavirus Hpv Testing by: Type (Value)
        • 5.2.1.1. HPV Testing
        • 5.2.1.2. Pap Test
      • 5.2.2. Global Papillomavirus Hpv Testing by: Application (Value)
        • 5.2.2.1. Cervical Cancer Screening
        • 5.2.2.2. Vaginal Cancer Screening
        • 5.2.2.3. Molecular Diagnostics
        • 5.2.2.4. Research Use
      • 5.2.3. Global Papillomavirus Hpv Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Papillomavirus Hpv Testing (Price)
      • 5.3.1. Global Papillomavirus Hpv Testing by: Type (Price)
  • 6. Papillomavirus Hpv Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hologic Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cepheid Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Seegene Inc. (South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Promega Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Greiner Bio-One International GmbH (Austria)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Enzo Biochem Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thermo Fisher Scientific Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takara Bio Inc. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Agilent Technologies, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Norgen Biotek Corp. (Canada)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. DiagCor Bioscience Inc Ltd (China)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Hybribio Limited (China)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Zytovision GmbH (Germany)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Papillomavirus Hpv Testing Sale, by Type, Application, End User , Product and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Papillomavirus Hpv Testing (Value)
      • 7.2.1. Global Papillomavirus Hpv Testing by: Type (Value)
        • 7.2.1.1. HPV Testing
        • 7.2.1.2. Pap Test
      • 7.2.2. Global Papillomavirus Hpv Testing by: Application (Value)
        • 7.2.2.1. Cervical Cancer Screening
        • 7.2.2.2. Vaginal Cancer Screening
        • 7.2.2.3. Molecular Diagnostics
        • 7.2.2.4. Research Use
      • 7.2.3. Global Papillomavirus Hpv Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Papillomavirus Hpv Testing (Price)
      • 7.3.1. Global Papillomavirus Hpv Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Papillomavirus Hpv Testing: by Type(USD Million)
  • Table 2. Papillomavirus Hpv Testing HPV Testing , by Region USD Million (2017-2022)
  • Table 3. Papillomavirus Hpv Testing Pap Test , by Region USD Million (2017-2022)
  • Table 4. Papillomavirus Hpv Testing: by Application(USD Million)
  • Table 5. Papillomavirus Hpv Testing Cervical Cancer Screening , by Region USD Million (2017-2022)
  • Table 6. Papillomavirus Hpv Testing Vaginal Cancer Screening , by Region USD Million (2017-2022)
  • Table 7. Papillomavirus Hpv Testing Molecular Diagnostics , by Region USD Million (2017-2022)
  • Table 8. Papillomavirus Hpv Testing Research Use , by Region USD Million (2017-2022)
  • Table 9. South America Papillomavirus Hpv Testing, by Country USD Million (2017-2022)
  • Table 10. South America Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 11. South America Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 12. South America Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 13. South America Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 14. Brazil Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 15. Brazil Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 16. Brazil Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 17. Brazil Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 18. Argentina Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 19. Argentina Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 20. Argentina Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 21. Argentina Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 22. Rest of South America Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 23. Rest of South America Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 24. Rest of South America Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 25. Rest of South America Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 26. Asia Pacific Papillomavirus Hpv Testing, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 28. Asia Pacific Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 29. Asia Pacific Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 30. Asia Pacific Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 31. China Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 32. China Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 33. China Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 34. China Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 35. Japan Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 36. Japan Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 37. Japan Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 38. Japan Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 39. India Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 40. India Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 41. India Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 42. India Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 43. South Korea Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 44. South Korea Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 45. South Korea Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 46. South Korea Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 47. Australia Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 48. Australia Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 49. Australia Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 50. Australia Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 55. Europe Papillomavirus Hpv Testing, by Country USD Million (2017-2022)
  • Table 56. Europe Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 57. Europe Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 58. Europe Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 59. Europe Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 60. Germany Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 61. Germany Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 62. Germany Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 63. Germany Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 64. France Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 65. France Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 66. France Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 67. France Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 68. Italy Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 69. Italy Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 70. Italy Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 71. Italy Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 72. United Kingdom Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 73. United Kingdom Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 74. United Kingdom Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 75. United Kingdom Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 76. Netherlands Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 77. Netherlands Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 78. Netherlands Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 79. Netherlands Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 80. Rest of Europe Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 81. Rest of Europe Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 82. Rest of Europe Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 83. Rest of Europe Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 84. MEA Papillomavirus Hpv Testing, by Country USD Million (2017-2022)
  • Table 85. MEA Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 86. MEA Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 87. MEA Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 88. MEA Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 89. Middle East Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 90. Middle East Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 91. Middle East Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 92. Middle East Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 93. Africa Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 94. Africa Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 95. Africa Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 96. Africa Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 97. North America Papillomavirus Hpv Testing, by Country USD Million (2017-2022)
  • Table 98. North America Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 99. North America Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 100. North America Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 101. North America Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 102. United States Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 103. United States Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 104. United States Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 105. United States Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 106. Canada Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 107. Canada Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 108. Canada Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 109. Canada Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 110. Mexico Papillomavirus Hpv Testing, by Type USD Million (2017-2022)
  • Table 111. Mexico Papillomavirus Hpv Testing, by Application USD Million (2017-2022)
  • Table 112. Mexico Papillomavirus Hpv Testing, by End User USD Million (2017-2022)
  • Table 113. Mexico Papillomavirus Hpv Testing, by Product USD Million (2017-2022)
  • Table 114. Papillomavirus Hpv Testing: by Type(USD/Units)
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Papillomavirus Hpv Testing: by Type(USD Million)
  • Table 131. Papillomavirus Hpv Testing HPV Testing , by Region USD Million (2022-2027)
  • Table 132. Papillomavirus Hpv Testing Pap Test , by Region USD Million (2022-2027)
  • Table 133. Papillomavirus Hpv Testing: by Application(USD Million)
  • Table 134. Papillomavirus Hpv Testing Cervical Cancer Screening , by Region USD Million (2022-2027)
  • Table 135. Papillomavirus Hpv Testing Vaginal Cancer Screening , by Region USD Million (2022-2027)
  • Table 136. Papillomavirus Hpv Testing Molecular Diagnostics , by Region USD Million (2022-2027)
  • Table 137. Papillomavirus Hpv Testing Research Use , by Region USD Million (2022-2027)
  • Table 138. South America Papillomavirus Hpv Testing, by Country USD Million (2022-2027)
  • Table 139. South America Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 140. South America Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 141. South America Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 142. South America Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 143. Brazil Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 144. Brazil Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 145. Brazil Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 146. Brazil Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 147. Argentina Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 148. Argentina Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 149. Argentina Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 150. Argentina Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 151. Rest of South America Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 152. Rest of South America Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 153. Rest of South America Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 154. Rest of South America Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 155. Asia Pacific Papillomavirus Hpv Testing, by Country USD Million (2022-2027)
  • Table 156. Asia Pacific Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 157. Asia Pacific Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 158. Asia Pacific Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 159. Asia Pacific Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 160. China Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 161. China Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 162. China Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 163. China Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 164. Japan Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 165. Japan Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 166. Japan Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 167. Japan Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 168. India Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 169. India Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 170. India Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 171. India Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 172. South Korea Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 173. South Korea Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 174. South Korea Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 175. South Korea Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 176. Australia Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 177. Australia Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 178. Australia Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 179. Australia Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 180. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 181. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 182. Rest of Asia-Pacific Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 183. Rest of Asia-Pacific Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 184. Europe Papillomavirus Hpv Testing, by Country USD Million (2022-2027)
  • Table 185. Europe Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 186. Europe Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 187. Europe Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 188. Europe Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 189. Germany Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 190. Germany Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 191. Germany Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 192. Germany Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 193. France Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 194. France Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 195. France Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 196. France Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 197. Italy Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 198. Italy Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 199. Italy Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 200. Italy Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 201. United Kingdom Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 202. United Kingdom Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 203. United Kingdom Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 204. United Kingdom Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 205. Netherlands Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 206. Netherlands Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 207. Netherlands Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 208. Netherlands Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 209. Rest of Europe Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 210. Rest of Europe Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 211. Rest of Europe Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 212. Rest of Europe Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 213. MEA Papillomavirus Hpv Testing, by Country USD Million (2022-2027)
  • Table 214. MEA Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 215. MEA Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 216. MEA Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 217. MEA Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 218. Middle East Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 219. Middle East Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 220. Middle East Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 221. Middle East Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 222. Africa Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 223. Africa Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 224. Africa Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 225. Africa Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 226. North America Papillomavirus Hpv Testing, by Country USD Million (2022-2027)
  • Table 227. North America Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 228. North America Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 229. North America Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 230. North America Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 231. United States Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 232. United States Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 233. United States Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 234. United States Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 235. Canada Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 236. Canada Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 237. Canada Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 238. Canada Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 239. Mexico Papillomavirus Hpv Testing, by Type USD Million (2022-2027)
  • Table 240. Mexico Papillomavirus Hpv Testing, by Application USD Million (2022-2027)
  • Table 241. Mexico Papillomavirus Hpv Testing, by End User USD Million (2022-2027)
  • Table 242. Mexico Papillomavirus Hpv Testing, by Product USD Million (2022-2027)
  • Table 243. Papillomavirus Hpv Testing: by Type(USD/Units)
  • Table 244. Research Programs/Design for This Report
  • Table 245. Key Data Information from Secondary Sources
  • Table 246. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Papillomavirus Hpv Testing: by Type USD Million (2017-2022)
  • Figure 5. Global Papillomavirus Hpv Testing: by Application USD Million (2017-2022)
  • Figure 6. South America Papillomavirus Hpv Testing Share (%), by Country
  • Figure 7. Asia Pacific Papillomavirus Hpv Testing Share (%), by Country
  • Figure 8. Europe Papillomavirus Hpv Testing Share (%), by Country
  • Figure 9. MEA Papillomavirus Hpv Testing Share (%), by Country
  • Figure 10. North America Papillomavirus Hpv Testing Share (%), by Country
  • Figure 11. Global Papillomavirus Hpv Testing: by Type USD/Units (2017-2022)
  • Figure 12. Global Papillomavirus Hpv Testing share by Players 2022 (%)
  • Figure 13. Global Papillomavirus Hpv Testing share by Players (Top 3) 2022(%)
  • Figure 14. Global Papillomavirus Hpv Testing share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 18. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Hologic Inc. (United States) Revenue: by Geography 2022
  • Figure 20. Cepheid Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cepheid Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Seegene Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 23. Seegene Inc. (South Korea) Revenue: by Geography 2022
  • Figure 24. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 26. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Promega Corporation (United States) Revenue: by Geography 2022
  • Figure 28. Greiner Bio-One International GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 29. Greiner Bio-One International GmbH (Austria) Revenue: by Geography 2022
  • Figure 30. Enzo Biochem Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Enzo Biochem Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Takara Bio Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takara Bio Inc. (Japan) Revenue: by Geography 2022
  • Figure 36. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Agilent Technologies, Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Norgen Biotek Corp. (Canada) Revenue, Net Income and Gross profit
  • Figure 39. Norgen Biotek Corp. (Canada) Revenue: by Geography 2022
  • Figure 40. DiagCor Bioscience Inc Ltd (China) Revenue, Net Income and Gross profit
  • Figure 41. DiagCor Bioscience Inc Ltd (China) Revenue: by Geography 2022
  • Figure 42. Hybribio Limited (China) Revenue, Net Income and Gross profit
  • Figure 43. Hybribio Limited (China) Revenue: by Geography 2022
  • Figure 44. Zytovision GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 45. Zytovision GmbH (Germany) Revenue: by Geography 2022
  • Figure 46. Global Papillomavirus Hpv Testing: by Type USD Million (2022-2027)
  • Figure 47. Global Papillomavirus Hpv Testing: by Application USD Million (2022-2027)
  • Figure 48. South America Papillomavirus Hpv Testing Share (%), by Country
  • Figure 49. Asia Pacific Papillomavirus Hpv Testing Share (%), by Country
  • Figure 50. Europe Papillomavirus Hpv Testing Share (%), by Country
  • Figure 51. MEA Papillomavirus Hpv Testing Share (%), by Country
  • Figure 52. North America Papillomavirus Hpv Testing Share (%), by Country
  • Figure 53. Global Papillomavirus Hpv Testing: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Hologic Inc. (United States)
  • Cepheid Inc. (United States)
  • Seegene Inc. (South Korea)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Promega Corporation (United States)
  • Greiner Bio-One International GmbH (Austria)
  • Enzo Biochem Inc. (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • Takara Bio Inc. (Japan)
  • Agilent Technologies, Inc. (United States)
  • Norgen Biotek Corp. (Canada)
  • DiagCor Bioscience Inc Ltd (China)
  • Hybribio Limited (China)
  • Zytovision GmbH (Germany)
Additional players considered in the study are as follows:
Becton, Dickinson and Company (United States) , Qiagen N.V. (Netherland) , Arbor Vita Corporation (United States) , Medical & Biological Laboratories Co., Ltd (Japan) , Fujirebio Diagnostics, Inc. (Japan)
Select User Access Type

Key Highlights of Report


Sep 2022 216 Pages 81 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Papillomavirus Hpv Testing Market Quantitative research analysis
Global Papillomavirus Hpv Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Papillomavirus Hpv Testing Market are by type [HPV Testing and Pap Test], by end use application [Cervical Cancer Screening, Vaginal Cancer Screening, Molecular Diagnostics and Research Use].
The Papillomavirus Hpv Testing Market is gaining popularity and expected to see strong valuation by 2027.
  • The market is expanding due to an increase in cervical cancer screening programmes
  • Cervical cancer cases on the rise with an ageing population propelling the factor forward

Know More About Global Papillomavirus Hpv Testing Market Report?

Have a Query? Click Here

Other Related Reports

Paediatric Epilepsy Therapeutics Comprehensive Study by Application (Hospitals, Neurology Centers, Home Care Settings, Ambulatory Surgical Centers), Disease Type (Benign Rolandic Epilepsy, Childhood ...
$ 3800
European Online Pharmacy (E-Pharma) Comprehensive Study by Type (Prescription Drugs, Over-the-counter (OTC) Drugs), Application (Skin Care, Dental, Vitamins, Weight Loss, Others), Components (Web-Bas...
$ 3800
Emergency Ambulance Vehicle Comprehensive Study by Application (Hospitals, Emergency Center, Others), Ambulance Equipment (Advanced Life Support Ambulance Services (ALS), Basic Life Support Ambulance...
$ 3800
Gum Grafting Comprehensive Study by Type (Connective-tissue Grafts, Free Gingival Grafts, Pedicle Grafts, Alternative Grafts, Others), Material Type (Autografts, Allografts, Xenografts, Others), Tech...
$ 3800
Mental Health Apps Comprehensive Study by Application (Depression and Anxiety Management,, Stress Management, Meditation Management, Others), Deployment Mode (On-Premises, Cloud-Based), End User (Ho...
$ 3800
Healthcare Cold Chain Monitoring Comprehensive Study by Temperature (Frozen, Chilled), Product (Antibiotic Medications, Respiratory Medications, Vaccines, Proteins, Others), Component (Hardware Senso...
$ 3800